Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis

Bibliography

• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-2581
   PubMed Web of Science ®Google Scholar
• Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2014;73(1):114-23
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625-39
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of cochrane reviews. Sao Paulo Med J 2010;128(5):309-10
   PubMed Web of Science ®Google Scholar
• Jurgens MS, Welsing PM, Jacobs JW. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission. Clin Exp Rheumatol 2012;30(4 Suppl 73):S56-63
   PubMed Web of Science ®Google Scholar
• Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36(3):307-18
   PubMed Web of Science ®Google Scholar
• Moreland LW, Sewell KL, Trentham DE, et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum 1995;38(9):1177-86
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol 1996;35(3):231-40
   PubMedGoogle Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36(12):1681-90
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36(6):1118-25
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72(4):482-92
   PubMed Web of Science ®Google Scholar
• Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72(3):322-8
   PubMed Web of Science ®Google Scholar
• Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009;60(5):1210-21
   PubMed Web of Science ®Google Scholar
• Study of KB003 in biologics-inadequate rheumatoid arthritis - study results - ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00995449 [Accessed 20 February 2014]
   Google Scholar
• Behrens F, Tak PP, Ostergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58(5):1299-309
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
   PubMed Web of Science ®Google Scholar
• Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003;4(11):1369-76
   PubMedGoogle Scholar
• Furst DE, Weisman M, Paulus HE, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J Rheumatol 2003;30(10):2123-6
   PubMed Web of Science ®Google Scholar
• Stahl N, Radin A, Mellis S. Rilonacept--CAPS and beyond. Ann NY Acad Sci 2009;1182:124-34
   PubMed Web of Science ®Google Scholar
• Abatacept (orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006;48(1229):17-18
   PubMed Web of Science ®Google Scholar
• Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;(4):CD007277
   PubMed Web of Science ®Google Scholar
• Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 2012;14(4):303-9
   PubMedGoogle Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24(3):203-15
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63(7):1782-92
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63(7):1793-803
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Wei N, Shaw M, et al. BR3-Fc phase I study: safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(9):S229-30
   Web of Science ®Google Scholar
• Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002;4(Suppl 2):S22-8
   PubMedGoogle Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117(2):244-79
   PubMed Web of Science ®Google Scholar
• Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(2):235-49
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3):286-92
   PubMed Web of Science ®Google Scholar
• Zhao Q, Pang J, Shuster D, et al. Anti-IL-6 antibody clazakizumab is more potent than tocilizumab in blocking in vitro and ex vivo IL-6-induced functions. Arthritis Rheum 2013;65:S1020-0
   Web of Science ®Google Scholar
• New sirukumab (CNTO 136) phase 2 data show efficacy of interleukin-6 inhibitor across multiple dose regimens in treatment of rheumatoid arthritis (NYSE:JNJ). Available from: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=621281 [Accessed 20 February 2014]
   Google Scholar
• Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord 2011;12:153
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol 2013;40(5):579-89
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013;72(9):1461-8
   PubMed Web of Science ®Google Scholar
• Jin X, Ding C. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis. Expert Opin Biol Ther 2013;13(2):315-22
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918-30
   PubMed Web of Science ®Google Scholar
• Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72(9):1453-60
   PubMed Web of Science ®Google Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):52ra72
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3(2):86-95
   PubMedGoogle Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58(9):2652-61
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62(8):2227-38
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73(1):69-74
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15(5):R164
   PubMed Web of Science ®Google Scholar
• Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013;72(9):1445-52
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7(1):e30275
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374(9685):210-21
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25(5):1131-42
   PubMed Web of Science ®Google Scholar
• Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003;25(6):1700-21
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343(22):1594-602
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72(12):1947-55
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305(14):1460-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121(5):1088-94
   PubMed Web of Science ®Google Scholar
• Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn’s disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002;973:166-80
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):85-95; quiz e14-5
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60(6):780-7
   PubMed Web of Science ®Google Scholar
• Da W, Zhu J, Wang L, Lu Y. Efficacy and safety of certolizumab pegol for crohn’s disease: a systematic review and meta-analysis. Adv Ther 2013;30(5):541-53
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs 2013;73(4):341-56
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2013;32(10):1415-24
   PubMed Web of Science ®Google Scholar
• Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) 2014. [Epub ahead of print]
   Google Scholar
• Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63(10):2854-64
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65(1):28-38
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Vincenti F. Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biologics 2012;6:385-93
   PubMedGoogle Scholar
• Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10):1018-28
   PubMed Web of Science ®Google Scholar
• Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70(12):2119-25
   PubMed Web of Science ®Google Scholar
• Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 2013;40(7):1089-96
   PubMed Web of Science ®Google Scholar
• Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012;71(8):1289-96
   PubMed Web of Science ®Google Scholar
• Reddy V, Croca S, Gerona D, et al. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) 2013;52(5):951-2
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2013;65(4):880-9
   PubMed Web of Science ®Google Scholar
• Combe B, van Vollenhoven R. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. Ann Rheum Dis 2013;72(9):1433-5
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73(1):86-94
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67(8):1096-103
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64(3):617-29
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367(6):508-19
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381(9877):1541-50
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-7
   PubMed Web of Science ®Google Scholar
• Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33(5):854-61
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(7):889-94
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60(7):1884-94
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis 2010;69(3):522-8
   PubMed Web of Science ®Google Scholar
• Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194(4):486-92
   PubMed Web of Science ®Google Scholar
• Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48(8):883-6
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348(1-2):36-41
   PubMed Web of Science ®Google Scholar
• Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59(7):996-1001
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Bene J, et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS ONE 2012;7(11):e48991
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72(9):1496-502
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a cochrane systematic review. J Rheumatol 2010;37(2):234-45
   PubMed Web of Science ®Google Scholar
• Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013;52(6):986-97
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13(5):R141
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 2013. [Epub ahead of print]
   Web of Science ®Google Scholar